Brands fear effects of ANDA venue win – but should they?
BMS, Sanofi and others say a Federal Circuit ruling, if affirmed in a rehearing, could reshape Hatch-Waxman litigation. Others think it only affects Mylan
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: